Early and late treatment failure in community-acquired pneumonia.
Identifieur interne : 000530 ( Main/Exploration ); précédent : 000529; suivant : 000531Early and late treatment failure in community-acquired pneumonia.
Auteurs : Carolina Garcia-Vidal [Espagne] ; Jordi CarratalàSource :
- Seminars in respiratory and critical care medicine [ 1098-9048 ] ; 2009.
Descripteurs français
- KwdFr :
- Antibactériens (usage thérapeutique), Espagne (épidémiologie), Facteurs de risque (MeSH), Guides de bonnes pratiques cliniques comme sujet (MeSH), Hospitalisation (MeSH), Humains (MeSH), Incidence (MeSH), Infections communautaires (traitement médicamenteux), Médecine factuelle (MeSH), Pneumopathie bactérienne (traitement médicamenteux), Résistance microbienne aux médicaments (MeSH), Échec thérapeutique (MeSH).
- MESH :
- traitement médicamenteux : Infections communautaires, Pneumopathie bactérienne.
- usage thérapeutique : Antibactériens.
- épidémiologie : Espagne.
- Facteurs de risque, Guides de bonnes pratiques cliniques comme sujet, Hospitalisation, Humains, Incidence, Médecine factuelle, Résistance microbienne aux médicaments, Échec thérapeutique.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Anti-Bacterial Agents (therapeutic use), Community-Acquired Infections (drug therapy), Drug Resistance, Microbial (MeSH), Evidence-Based Medicine (MeSH), Hospitalization (MeSH), Humans (MeSH), Incidence (MeSH), Pneumonia, Bacterial (drug therapy), Practice Guidelines as Topic (MeSH), Risk Factors (MeSH), Spain (epidemiology), Treatment Failure (MeSH).
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents.
- geographic , epidemiology : Spain.
- drug therapy : Community-Acquired Infections, Pneumonia, Bacterial.
- Drug Resistance, Microbial, Evidence-Based Medicine, Hospitalization, Humans, Incidence, Practice Guidelines as Topic, Risk Factors, Treatment Failure.
Abstract
Treatment failure is a matter of great concern in the management of community-acquired pneumonia (CAP). Defined generally as lack of response or clinical deterioration, failure is considered early when it occurs within the first 72 hours and late when it occurs after 72 hours. The reported incidence of treatment failure among hospitalized patients with CAP ranges from 2.4 to 31% for early failure and from 3.9 to 11% for late failure. Most cases of early failure occur because of inadequate host-pathogen responses. Factors associated with treatment failure include high-risk pneumonia, liver disease, multilobar infiltrates, Legionella pneumonia, gram-negative pneumonia, pleural effusion, cavitation, leucopenia, and discordant antimicrobial therapy. Conversely, influenza vaccination, initial treatment with fluoroquinolones, and chronic obstructive pulmonary disease have been linked with a lower risk of failure. Treatment failure is associated with high morbidity and mortality rates. Its detection and management require careful clinical assessment. Certain serum biological markers may be helpful to identify patients with a higher risk of deterioration and poor prognosis. Because inadequate host-pathogen responses are responsible for a significant number of failures, strategies aimed at modulating the inflammatory response should be investigated. Discordant therapy can be prevented by rational application of the current antibiotic guidelines.
DOI: 10.1055/s-0029-1202934
PubMed: 19296415
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early and late treatment failure in community-acquired pneumonia.</title><author><name sortKey="Garcia Vidal, Carolina" sort="Garcia Vidal, Carolina" uniqKey="Garcia Vidal C" first="Carolina" last="Garcia-Vidal">Carolina Garcia-Vidal</name><affiliation wicri:level="3"><nlm:affiliation>Infectious Disease Service, Hospital Universitari de Bellvitge. Institut d'investigació Biomèdica de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Infectious Disease Service, Hospital Universitari de Bellvitge. Institut d'investigació Biomèdica de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Carratala, Jordi" sort="Carratala, Jordi" uniqKey="Carratala J" first="Jordi" last="Carratalà">Jordi Carratalà</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19296415</idno><idno type="pmid">19296415</idno><idno type="doi">10.1055/s-0029-1202934</idno><idno type="wicri:Area/Main/Corpus">00526</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00526</idno><idno type="wicri:Area/Main/Curation">000526</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000526</idno><idno type="wicri:Area/Main/Exploration">000526</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Early and late treatment failure in community-acquired pneumonia.</title><author><name sortKey="Garcia Vidal, Carolina" sort="Garcia Vidal, Carolina" uniqKey="Garcia Vidal C" first="Carolina" last="Garcia-Vidal">Carolina Garcia-Vidal</name><affiliation wicri:level="3"><nlm:affiliation>Infectious Disease Service, Hospital Universitari de Bellvitge. Institut d'investigació Biomèdica de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Infectious Disease Service, Hospital Universitari de Bellvitge. Institut d'investigació Biomèdica de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Carratala, Jordi" sort="Carratala, Jordi" uniqKey="Carratala J" first="Jordi" last="Carratalà">Jordi Carratalà</name></author></analytic><series><title level="j">Seminars in respiratory and critical care medicine</title><idno type="eISSN">1098-9048</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (therapeutic use)</term><term>Community-Acquired Infections (drug therapy)</term><term>Drug Resistance, Microbial (MeSH)</term><term>Evidence-Based Medicine (MeSH)</term><term>Hospitalization (MeSH)</term><term>Humans (MeSH)</term><term>Incidence (MeSH)</term><term>Pneumonia, Bacterial (drug therapy)</term><term>Practice Guidelines as Topic (MeSH)</term><term>Risk Factors (MeSH)</term><term>Spain (epidemiology)</term><term>Treatment Failure (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antibactériens (usage thérapeutique)</term><term>Espagne (épidémiologie)</term><term>Facteurs de risque (MeSH)</term><term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term><term>Hospitalisation (MeSH)</term><term>Humains (MeSH)</term><term>Incidence (MeSH)</term><term>Infections communautaires (traitement médicamenteux)</term><term>Médecine factuelle (MeSH)</term><term>Pneumopathie bactérienne (traitement médicamenteux)</term><term>Résistance microbienne aux médicaments (MeSH)</term><term>Échec thérapeutique (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Community-Acquired Infections</term><term>Pneumonia, Bacterial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections communautaires</term><term>Pneumopathie bactérienne</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Resistance, Microbial</term><term>Evidence-Based Medicine</term><term>Hospitalization</term><term>Humans</term><term>Incidence</term><term>Practice Guidelines as Topic</term><term>Risk Factors</term><term>Treatment Failure</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs de risque</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Hospitalisation</term><term>Humains</term><term>Incidence</term><term>Médecine factuelle</term><term>Résistance microbienne aux médicaments</term><term>Échec thérapeutique</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Treatment failure is a matter of great concern in the management of community-acquired pneumonia (CAP). Defined generally as lack of response or clinical deterioration, failure is considered early when it occurs within the first 72 hours and late when it occurs after 72 hours. The reported incidence of treatment failure among hospitalized patients with CAP ranges from 2.4 to 31% for early failure and from 3.9 to 11% for late failure. Most cases of early failure occur because of inadequate host-pathogen responses. Factors associated with treatment failure include high-risk pneumonia, liver disease, multilobar infiltrates, Legionella pneumonia, gram-negative pneumonia, pleural effusion, cavitation, leucopenia, and discordant antimicrobial therapy. Conversely, influenza vaccination, initial treatment with fluoroquinolones, and chronic obstructive pulmonary disease have been linked with a lower risk of failure. Treatment failure is associated with high morbidity and mortality rates. Its detection and management require careful clinical assessment. Certain serum biological markers may be helpful to identify patients with a higher risk of deterioration and poor prognosis. Because inadequate host-pathogen responses are responsible for a significant number of failures, strategies aimed at modulating the inflammatory response should be investigated. Discordant therapy can be prevented by rational application of the current antibiotic guidelines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19296415</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2009</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-9048</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Seminars in respiratory and critical care medicine</Title><ISOAbbreviation>Semin Respir Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Early and late treatment failure in community-acquired pneumonia.</ArticleTitle><Pagination><MedlinePgn>154-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0029-1202934</ELocationID><Abstract><AbstractText>Treatment failure is a matter of great concern in the management of community-acquired pneumonia (CAP). Defined generally as lack of response or clinical deterioration, failure is considered early when it occurs within the first 72 hours and late when it occurs after 72 hours. The reported incidence of treatment failure among hospitalized patients with CAP ranges from 2.4 to 31% for early failure and from 3.9 to 11% for late failure. Most cases of early failure occur because of inadequate host-pathogen responses. Factors associated with treatment failure include high-risk pneumonia, liver disease, multilobar infiltrates, Legionella pneumonia, gram-negative pneumonia, pleural effusion, cavitation, leucopenia, and discordant antimicrobial therapy. Conversely, influenza vaccination, initial treatment with fluoroquinolones, and chronic obstructive pulmonary disease have been linked with a lower risk of failure. Treatment failure is associated with high morbidity and mortality rates. Its detection and management require careful clinical assessment. Certain serum biological markers may be helpful to identify patients with a higher risk of deterioration and poor prognosis. Because inadequate host-pathogen responses are responsible for a significant number of failures, strategies aimed at modulating the inflammatory response should be investigated. Discordant therapy can be prevented by rational application of the current antibiotic guidelines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Vidal</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Disease Service, Hospital Universitari de Bellvitge. Institut d'investigació Biomèdica de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carratalà</LastName><ForeName>Jordi</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Respir Crit Care Med</MedlineTA><NlmUniqueID>9431858</NlmUniqueID><ISSNLinking>1069-3424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017714" MajorTopicYN="N">Community-Acquired Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004352" MajorTopicYN="Y">Drug Resistance, Microbial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018410" MajorTopicYN="N">Pneumonia, Bacterial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>37</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19296415</ArticleId><ArticleId IdType="doi">10.1055/s-0029-1202934</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><noCountry><name sortKey="Carratala, Jordi" sort="Carratala, Jordi" uniqKey="Carratala J" first="Jordi" last="Carratalà">Jordi Carratalà</name></noCountry><country name="Espagne"><region name="Catalogne"><name sortKey="Garcia Vidal, Carolina" sort="Garcia Vidal, Carolina" uniqKey="Garcia Vidal C" first="Carolina" last="Garcia-Vidal">Carolina Garcia-Vidal</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000530 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000530 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19296415
|texte= Early and late treatment failure in community-acquired pneumonia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19296415" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |